AYAL Capital Advisors Ltd Invests $376,000 in Profound Medical Corp. (NASDAQ:PROF)

AYAL Capital Advisors Ltd bought a new position in shares of Profound Medical Corp. (NASDAQ:PROF - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $376,000. AYAL Capital Advisors Ltd owned 0.17% of Profound Medical as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gagnon Securities LLC lifted its position in shares of Profound Medical by 12.6% in the fourth quarter. Gagnon Securities LLC now owns 1,652,531 shares of the company's stock worth $12,411,000 after purchasing an additional 185,284 shares in the last quarter. Gagnon Advisors LLC lifted its stake in Profound Medical by 20.0% in the fourth quarter. Gagnon Advisors LLC now owns 896,671 shares of the company's stock valued at $6,734,000 after acquiring an additional 149,445 shares during the last quarter. Truist Financial Corp bought a new stake in Profound Medical in the fourth quarter worth approximately $376,000. Ring Mountain Capital LLC acquired a new position in shares of Profound Medical during the 4th quarter worth $2,087,000. Finally, Vestcor Inc acquired a new stake in shares of Profound Medical in the 4th quarter valued at $376,000. Institutional investors and hedge funds own 47.86% of the company's stock.

Profound Medical Stock Performance

PROF traded up $0.18 during trading on Thursday, hitting $4.99. The stock had a trading volume of 55,254 shares, compared to its average volume of 60,389. Profound Medical Corp. has a 12 month low of $3.90 and a 12 month high of $11.42. The firm has a market cap of $149.96 million, a PE ratio of -3.72 and a beta of 0.44. The company has a 50 day simple moving average of $5.67 and a 200-day simple moving average of $6.78. The company has a current ratio of 6.12, a quick ratio of 5.16 and a debt-to-equity ratio of 0.11.

Profound Medical (NASDAQ:PROF - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.11. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. The company had revenue of $4.18 million for the quarter, compared to analyst estimates of $5.92 million. Analysts expect that Profound Medical Corp. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

Separately, Lake Street Capital cut their price objective on Profound Medical from $17.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.